N/A
Completed N=12
Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment
Source: ClinicalTrials.gov NCT05258058 ↗Enrolled (actual)
12
Serious AEs
0.0%
Results posted
Jul 2024
Primary outcomePrimary: MAAT-G Feasibility Completion Rate — 10 Participants
Summary
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training-Geriatrics (MAAT-G) is a cognitive behavioral therapy-based intervention tailored specifically for older adults and the feasibility of MAAT-G in older cancer survivors with Mild Cognitive Impairment (MCI) is being evaluated.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MAAT-G Feasibility Completion Rate |
10 | — |
| PRIMARY MAAT-G Intervention Adherence Rate |
88.33 | — |
| SECONDARY Proportion of Patients Who Described at Least One MAAT-G Skill |
9 | — |
| SECONDARY Change in Cognitive Function (Pre-Post Changes Functional Assessment of Cancer Therapy-Cognition [FACT-Cog]) |
6.39 | — |
| SECONDARY Mean Usability |
78.75 | — |
Eligibility Criteria
Inclusion Criteria
- Be age 65 or older
- Able to provide informed consent. All patients will be assessed using the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC)56 - a score >14.5 will define ability to independently provide informed consent. For patients scoring <14.5, or if investigators have additional concerns, we will require that their health care proxy participate in the consenting process and sign an informed consent and patients will required to provide assent.
- Able to read and understand English
- Have a prior diagnosis of cancer and completed curative intent chemotherapy. Patients are permitted to be receiving maintenance therapy (e.g. endocrine therapy) in the adjuvant setting.
- Have a clinical diagnosis of MCI, a score <26 on the Montreal Cognitive Assessment (MOCA), or a score <18 on the Montreal Cognitive Assessment-BLIND (MOCA-BLIND). If the patient had a MOCA evaluation completed as a part of routine clinical care in the preceding 3 months prior to consent date, this may be used for eligibility purposes.
- Be independent in Activities of Daily Living (ADL)
Data sourced from ClinicalTrials.gov (NCT05258058). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.